Which of the following is true about proto-oncogenes?
Mitochondrial chromosomal abnormality leads to which of the following conditions?
Congo red staining of abdominal fat has confirmed a diagnosis of Amyloidosis in a 28-year-old man. Which is the most common cause of death in primary AL Amyloidosis?
Karyotyping is useful in the diagnosis of which type of condition?
A 56-year-old male patient complains of swelling in his legs. He is a known case of hypertension and is under treatment. On general physical examination, pitting edema is seen on the legs, and his TSH level is 3 mU/L. Which of the following is not a cause of this condition?
Supratemporal lenticular subluxation is seen in which condition?
What is true about autosomal dominant inheritance?
Which of the following is NOT a form of reversible cellular injury?
Hemosiderin contains which of the following elements?
Annexin V is associated with which of the following processes?
Explanation: **Explanation:** **1. Why Option A is Correct:** Proto-oncogenes are **normal cellular genes** [1] that encode proteins essential for regulating cell growth, proliferation, and differentiation [2]. They function as the "accelerators" of the cell cycle [3]. Under normal physiological conditions, their activity is strictly regulated to ensure tissue homeostasis [1]. **2. Analysis of Incorrect Options:** * **Option B:** While proto-oncogenes can lead to cancer, they are not inherently "involved in oncogenesis" in their normal state. It is their **mutated or overexpressed forms**, known as **oncogenes**, that drive oncogenesis [2]. This distinction is a common examiner trap. * **Option C:** While *c-myc* is a proto-oncogene, its overexpression is specifically associated with **Burkitt Lymphoma** (via t(8;14) translocation). The statement is too broad; not all lymphomas are caused by *c-myc*. * **Option D:** Retinoblastoma is caused by a mutation in the **RB gene**, which is a **Tumor Suppressor Gene (TSG)**, not a proto-oncogene [1]. Proto-oncogenes require a "gain-of-function" mutation (dominant), whereas TSGs like RB require a "loss-of-function" (recessive/two-hit) mutation to cause malignancy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Proto-oncogenes become oncogenes via point mutations, chromosomal translocations, or gene amplification [5]. * **Key Examples:** * **RAS:** Most common mutated proto-oncogene in human tumors (Point mutation). * **ERBB2 (HER2/neu):** Amplified in Breast Cancer [4]. * **N-myc:** Amplified in Neuroblastoma. * **ABL:** Translocated in CML [t(9;22)]. * **Rule of Thumb:** Proto-oncogenes = Gain of function (1 allele mutation enough); Tumor Suppressor Genes = Loss of function (2 alleles mutation needed). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 228-229. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 292-293. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 291-292. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 292. [5] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 229-230.
Explanation: **Explanation:** **Leber’s Hereditary Optic Neuropathy (LHON)** is the correct answer because it is a classic example of a disorder caused by **mitochondrial DNA (mtDNA) mutations** [1]. Since mitochondria are inherited exclusively from the oocyte, LHON follows a **maternal inheritance pattern** (all children of an affected mother are at risk, but affected fathers do not pass it to their offspring). Pathophysiologically, mutations in mtDNA genes (encoding subunits of NADH dehydrogenase) lead to defective oxidative phosphorylation, causing selective degeneration of retinal ganglion cells and subsequent bilateral central vision loss. **Analysis of Incorrect Options:** * **Angelman Syndrome & Prader-Willi Syndrome:** These are examples of **Genomic Imprinting** (epigenetic regulation) involving chromosome 15 [1]. Angelman results from the loss of the maternal allele (UBE3A gene), while Prader-Willi results from the loss of the paternal allele. * **Myotonic Dystrophy:** This is a **Trinucleotide Repeat Disorder** (CTG repeat in the DMPK gene) [1]. It follows an Autosomal Dominant pattern and exhibits "anticipation." **High-Yield Clinical Pearls for NEET-PG:** * **Mitochondrial DNA (mtDNA):** It is circular, double-stranded, and lacks histones. It has a higher mutation rate than nuclear DNA. * **Heteroplasmy:** This term refers to the coexistence of wild-type and mutated mtDNA within a single cell [1]. The severity of mitochondrial diseases depends on the proportion of mutated mtDNA (Threshold effect) [1]. * **Other Mitochondrial Diseases:** MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) and MERRF (Myoclonic Epilepsy with Ragged Red Fibers). * **Histology:** "Ragged Red Fibers" on Gomori trichrome stain are a hallmark of mitochondrial myopathies. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 177, 181.
Explanation: **Explanation:** **Primary AL (Amyloid Light-chain) Amyloidosis** is characterized by the deposition of monoclonal immunoglobulin light chains, typically associated with plasma cell dyscrasias [1]. **Why Cardiac Failure is Correct:** The heart is the most critical organ involved in AL amyloidosis. Amyloid fibrils infiltrate the myocardium, leading to **Restrictive Cardiomyopathy** [2]. This results in diastolic dysfunction, thickened ventricular walls (often showing a "sparkling" or "granular" appearance on echocardiography), and fatal arrhythmias. **Cardiac failure and sudden cardiac death** are the leading causes of mortality, accounting for approximately 50-60% of deaths in these patients. **Analysis of Incorrect Options:** * **Renal Failure (Option C):** While the kidney is the most common organ involved in *Secondary (AA) Amyloidosis* and a frequent site in AL amyloidosis (causing nephrotic syndrome), it is no longer the leading cause of death due to advancements in dialysis and renal management. * **Respiratory Failure (Option A):** Pulmonary involvement can occur (tracheobronchial or alveolar septal deposits), but it rarely leads to terminal respiratory failure compared to cardiac complications. * **Septicemia (Option D):** While patients may be immunocompromised due to underlying plasma cell disorders or chemotherapy, sepsis is a secondary complication rather than the primary pathological cause of death. **High-Yield Clinical Pearls for NEET-PG:** * **Staining:** Amyloid shows **Apple-green birefringence** under polarized light with Congo red stain [3]. * **Diagnosis:** Abdominal fat pad biopsy is a high-yield, non-invasive screening test (as mentioned in the stem). * **Cardiac Biomarkers:** NT-proBNP and Troponins are the most important prognostic markers in AL amyloidosis. * **AA Amyloidosis:** Most common cause of death is **Renal Failure** (associated with chronic inflammation like TB or RA). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 266-267. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Heart, pp. 580-581. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 268-269.
Explanation: **Explanation:** **Karyotyping** is a cytogenetic technique used to examine the complete set of chromosomes in a cell. It involves arresting cells in **metaphase** (using colchicine), staining them (usually G-banding), and arranging them in a systematic order [1], [2]. **1. Why the Correct Answer is Right:** Karyotyping is specifically designed to detect **chromosomal abnormalities**, which include: * **Numerical abnormalities:** Aneuploidy (e.g., Trisomy 21 in Down Syndrome, 45,X in Turner Syndrome) [1], [3]. * **Structural abnormalities:** Large-scale changes visible under a light microscope, such as translocations (e.g., t(9;22) in CML), deletions (e.g., 5p deletion in Cri-du-chat), and inversions [4]. **2. Why Other Options are Incorrect:** * **Options A & B (Autosomal and X-linked Recessive Disorders):** These are **Mendelian (single-gene) disorders** caused by point mutations, small insertions, or deletions within a specific DNA sequence. These changes are too minute to be seen on a karyotype and require molecular techniques like PCR or DNA sequencing. * **Option D (Biochemical Abnormalities):** These refer to metabolic derangements (e.g., Phenylketonuria). These are diagnosed via biochemical assays (measuring enzyme activity or metabolite levels), not by visualizing chromosomes. **3. NEET-PG High-Yield Pearls:** * **Resolution:** Standard karyotyping can only detect structural changes larger than **5–10 Megabases (Mb)**. For smaller microdeletions (e.g., DiGeorge Syndrome), **FISH** (Fluorescence In Situ Hybridization) is the investigation of choice. * **Sample Source:** Most commonly performed on **phytohemagglutinin-stimulated T-lymphocytes**. * **Best Stage:** Chromosomes are most condensed and visible during **Metaphase** [2]. * **Amniocentesis:** Karyotyping is a gold standard for prenatal diagnosis of chromosomal trisomies in high-risk pregnancies. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 54-55. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 167-168. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 168-169. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 170-171.
Explanation: **Explanation:** The clinical presentation describes **pitting edema**, characterized by the displacement of interstitial fluid upon pressure, leaving a persistent indentation. This occurs when the edema fluid is a **transudate** (low protein content), typically driven by hemodynamic imbalances [1]. **Why Myxedema is the Correct Answer:** Myxedema is a feature of severe **hypothyroidism** (though the patient’s TSH of 3 mU/L is within the normal range, ruling it out). Unlike the pitting edema described, myxedema is **non-pitting**. It is caused by the deposition of glycosaminoglycans (like hyaluronic acid) in the dermis, which binds water into a gel-like matrix that cannot be easily displaced by pressure. **Analysis of Incorrect Options:** * **A. Increase in hydrostatic pressure:** This is a classic cause of pitting edema [2]. In conditions like Congestive Heart Failure (CHF) or deep vein thrombosis, increased venous pressure forces fluid out of capillaries into the interstitium [1]. * **B. Decreased colloid osmotic pressure:** Reduced plasma albumin (due to Nephrotic syndrome, cirrhosis, or malnutrition) lowers the osmotic "pull" that keeps fluid in vessels, leading to systemic pitting edema [2], [4]. * **C. Lymphatic obstruction:** While chronic lymphedema can eventually become non-pitting due to fibrosis, in its earlier stages or specific distributions, it involves the accumulation of interstitial fluid [1], [3]. However, in the context of general hemodynamic causes of leg swelling, it remains a standard mechanism for fluid accumulation. **NEET-PG High-Yield Pearls:** * **Pitting Edema:** Think "Starling Forces" (↑ Hydrostatic pressure or ↓ Oncotic pressure). Common in Heart Failure, Renal failure, and Liver failure. * **Non-Pitting Edema:** Think "Structural changes" (Myxedema in hypothyroidism or Elephantiasis/Lymphedema in late-stage lymphatic obstruction). * **Pre-tibial Myxedema:** Paradoxically occurs in **Graves' disease** (hyperthyroidism) due to fibroblast stimulation. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 124-126. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 124. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 125-126. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 126-127.
Explanation: **Explanation:** The correct answer is **Marfan Syndrome**. The question tests the clinical manifestation of connective tissue disorders, specifically the direction of **Ectopia Lentis** (dislocation of the lens). **1. Why Marfan Syndrome is correct:** Marfan syndrome is an autosomal dominant disorder caused by a mutation in the **FBN1 gene** on chromosome 15, leading to defective **Fibrillin-1**. Fibrillin is a major component of the suspensory ligaments (zonules) of the lens [1]. In Marfan syndrome, these zonules are weak, typically causing the lens to dislocate in a **superior and temporal (upward and outward)** direction. Skeletal abnormalities are also a striking feature of this syndrome [1]. **2. Why other options are incorrect:** * **Homocystinuria:** This is the most important differential. It is characterized by a deficiency of cystathionine beta-synthase. Crucially, the lens subluxation here is typically **inferomedial (downward and inward)**. Patients also exhibit intellectual disability and a high risk of thromboembolism, which are absent in Marfan. * **Weil’s Disease:** This is a severe form of Leptospirosis characterized by jaundice, renal failure, and hemorrhage. It has no association with lens subluxation. * **Hunter Syndrome:** A type of Mucopolysaccharidosis (MPS II). While it involves skeletal deformities, it is characterized by clear corneas (unlike Hurler syndrome) and does not typically present with ectopia lentis. **Clinical Pearls for NEET-PG:** * **Mnemonic for Lens Dislocation:** **M**arfan = **M**ountain (Up); **H**omocystinuria = **H**ell (Down). * **Marfan Syndrome:** Look for arachnodactyly, arm span > height, and **Aortic Dissection** (most common cause of death) or Mitral Valve Prolapse (MVP) [1]. * **Homocystinuria:** High yield association with **sticky platelets** and premature cardiovascular events. * **Other causes of Ectopia Lentis:** Weill-Marchesani syndrome (downward), Sulfite oxidase deficiency, and trauma (most common cause overall). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 153-154.
Explanation: ### Explanation **1. Why Option D is Correct:** Autosomal Dominant (AD) inheritance occurs when a single copy of a mutant allele (A) is sufficient to cause the disease phenotype [1]. In the most common clinical scenario, one parent is heterozygous affected (**Aa**) and the other is homozygous normal (**aa**). * **Punnett Square:** (Aa x aa) results in offspring genotypes: **Aa, Aa, aa, aa**. * **Outcome:** 50% of the offspring will be affected (Aa) and 50% will be normal (aa). There is no "carrier" state in AD disorders because anyone with the gene expresses the disease. **2. Why Other Options are Incorrect:** * **Option A:** This describes the classic ratio for **Autosomal Recessive (AR)** inheritance when both parents are carriers (Aa x Aa) [1]. In AD, if one parent is affected, 50% are affected, not 25%. * **Option B & C:** If both parents are affected (Aa x Aa), the Punnett square yields: **AA (25%), Aa (50%), and aa (25%)**. * Since both AA and Aa express the phenotype, **75% are affected**. * Option B is incorrect because "carrier" status does not apply to AD. Option C is technically correct for the phenotype ratio, but Option D is the standard textbook definition used to describe AD inheritance patterns in clinical exams. **3. NEET-PG High-Yield Pearls:** * **Vertical Transmission:** AD disorders appear in every generation (no skipping). * **Structural Proteins:** AD mutations usually involve **structural proteins** (e.g., Collagen in Osteogenesis Imperfecta) or **receptors** (e.g., LDL receptor in Familial Hypercholesterolemia) [2]. In contrast, AR mutations usually involve **enzymes** [2]. * **Key Concepts:** * **Reduced Penetrance:** Carrying the gene but not expressing the phenotype. * **Variable Expressivity:** Everyone with the gene expresses it, but to different degrees of severity (e.g., Neurofibromatosis). * **Pleiotropy:** A single gene mutation leading to multiple phenotypic effects (e.g., Marfan Syndrome). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 53-54. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 57-58.
Explanation: **Explanation:** The distinction between reversible and irreversible cell injury is a fundamental concept in pathology. The hallmark of **irreversible injury** is the loss of membrane integrity and severe nuclear changes, leading to cell death (necrosis or apoptosis) [1]. **Why Karyorrhexis is the correct answer:** Karyorrhexis refers to the **fragmentation of the nucleus** following pyknosis (nuclear shrinkage). It is a definitive sign of **irreversible cell injury** and necrosis [1]. Once the nucleus undergoes fragmentation or dissolution (karyolysis), the cell has passed the "point of no return" and cannot recover. **Analysis of Incorrect Options (Reversible Changes):** * **Cell Swelling (Hydropic Change):** This is the **first manifestation** of almost all forms of injury to cells [1]. It results from the failure of energy-dependent ion pumps (Na⁺-K⁺ ATPase), leading to an influx of water. It is fully reversible if the stimulus is removed. * **Vacuolar Degeneration:** This is an advanced stage of cell swelling where small clear vacuoles (representing distended endoplasmic reticulum) appear in the cytoplasm [1]. It remains a reversible process. * **Fat Accumulation (Steatosis):** This involves the abnormal accumulation of triglycerides within parenchymal cells (commonly the liver) [1]. While it indicates metabolic derangement, it is reversible. **High-Yield NEET-PG Pearls:** * **Earliest change in reversible injury:** Generalized swelling of the cell and its organelles (especially mitochondria) [1]. * **Hallmark of Irreversibility:** 1. Severe mitochondrial dysfunction (inability to generate ATP) and 2. Profound membrane damage (plasma, lysosomal, and mitochondrial membranes) [1]. * **Nuclear Sequence in Necrosis:** Pyknosis (clumping/shrinkage) → Karyorrhexis (fragmentation) → Karyolysis (dissolution by DNase) [1]. * **Myocardial Infarction:** The first ultrastructural change (reversible) is the depletion of glycogen and mitochondrial swelling. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 49-61.
Explanation: **Explanation:** **Hemosiderin** is an endogenous, iron-containing pigment that serves as one of the primary storage forms of iron in the body [3]. It is a golden-yellow to brown, granular or crystalline pigment derived from the breakdown of hemoglobin [1]. **1. Why Iron is Correct:** When red blood cells complete their lifespan or are destroyed (hemolysis), hemoglobin is released and broken down. The heme portion is further catabolized; while the porphyrin ring is converted to bilirubin, the **iron** is released. This iron is stored within cells (primarily macrophages in the spleen, liver, and bone marrow) as **ferritin** micelles [1]. When there is a local or systemic excess of iron, these ferritin micelles aggregate to form **hemosiderin** granules [1]. **2. Why Other Options are Incorrect:** * **Calcium:** While calcium is involved in pathologic calcification (dystrophic or metastatic), it is not a structural component of hemosiderin. * **Magnesium:** This is an intracellular cation involved in enzymatic reactions and bone structure, but it has no biochemical association with the formation of hemosiderin. **Clinical Pearls for NEET-PG:** * **Prussian Blue Stain (Perl’s Reaction):** This is the specific histochemical stain used to identify hemosiderin [2]. It reacts with the ferric iron to produce a characteristic **royal blue** color. * **Morphology:** On H&E stain, it appears as golden-yellow, refractile granules [2]. * **Local vs. Systemic:** Localized hemosiderosis is seen in common "bruises" (the color change from red-blue to golden-yellow) [1]. Systemic hemosiderosis occurs in conditions like hereditary hemochromatosis or multiple blood transfusions. * **Heart Failure Cells:** These are hemosiderin-laden macrophages found in the alveoli of patients with chronic passive congestion of the lungs (e.g., Left Heart Failure). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 75-76. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 854-855. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 657-658.
Explanation: **Explanation:** **Annexin V** is a cellular protein with a high affinity for **Phosphatidylserine (PS)** [1]. In healthy cells, PS is strictly localized to the inner leaflet (cytoplasmic side) of the plasma membrane [1]. During the early stages of **Apoptosis**, the enzyme *flippase* is inactivated and *scramblase* is activated, causing PS to "flip" to the outer leaflet [1]. This externalization of PS serves as an "eat-me" signal for phagocytes [1]. Because Annexin V binds specifically to externalized PS, it is used as a sensitive laboratory marker to identify and quantify apoptotic cells via flow cytometry. **Analysis of Incorrect Options:** * **Necrosis:** Unlike apoptosis, necrosis involves the early loss of membrane integrity and accidental cell rupture. While PS may be exposed, it is not a specific or regulated marker for necrosis. * **Atherosclerosis:** While apoptosis occurs within atherosclerotic plaques, Annexin V is not the primary pathological driver or clinical marker for the disease process itself. * **Inflammation:** Inflammation is a vascular and cellular response to injury. While apoptotic bodies are cleared without triggering inflammation, Annexin V is a marker of the cell death mechanism, not the inflammatory cascade [2]. **Clinical Pearls for NEET-PG:** * **Externalization of Phosphatidylserine:** The hallmark of early apoptosis detected by Annexin V [1]. * **Flippase vs. Scramblase:** Apoptosis involves the inhibition of P-type ATPase (flippase) and activation of scramblase [1]. * **Phagocytosis:** Externalized PS is recognized by receptors on macrophages (e.g., Tim-4), ensuring "silent" removal of cells without inflammation [2]. * **Other Markers:** Remember that **DNA laddering** (step-ladder pattern on electrophoresis) is a marker of late apoptosis due to internucleosomal cleavage by CAD (Caspase-Activated DNase). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. With Illustrations By, pp. 19-20. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 67-69.
Cell Injury and Cell Death
Practice Questions
Adaptations of Cellular Growth
Practice Questions
Accumulations and Deposits
Practice Questions
Acute and Chronic Inflammation
Practice Questions
Tissue Repair and Wound Healing
Practice Questions
Hemodynamic Disorders
Practice Questions
Genetic Disorders
Practice Questions
Environmental Pathology
Practice Questions
Nutritional Diseases
Practice Questions
Molecular Basis of Disease
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free